On October 30, 2026, the Office of Environmental Health Hazard Assessment (OEHHA), under the California Environmental Protection Agency, issued three notices of intent to list perfluorohexanoic acid (PFHxA), perfluorodecanoic acid (PFDA), and perfluorobutanoic acid (PFBA), along with their related salts, on the California Proposition 65 Reproductive Toxicant List. The deadline for public comment is November 30, 2026.
1. Perfluorohexanoic Acid (PFHxA, CASRN 307-24-4) and Related Salts
Basis: U.S. EPA IRIS Toxicological Review published in 2023
Listing Rationale: OEHHA determined that it meets listing criteria, based on developmental toxicity endpoints
Key Findings:
- EPA Conclusion: "PFHxA is likely to cause developmental effects in humans under exposure conditions sufficient to produce high exposure"
- Animal studies (mice and rats) showed that oral exposure to PFHxA (≥100 mg/kg-day) resulted in decreased offspring body weight and increased mortality
- Based on this, EPA developed chronic and subchronic oral reference doses (RfD = 5×10⁻⁴ mg/kg-day), with decreased body weight in neonatal rats as the point of departure
2. Perfluorodecanoic Acid (PFDA, CASRN 335-76-2) and Related Salts
Basis: U.S. EPA IRIS Toxicological Review published in 2024
Listing Rationale: OEHHA determined that it meets listing criteria, based on three endpoints: developmental toxicity, male reproductive toxicity, and female reproductive toxicity
Key Findings:
- EPA Conclusion: "PFDA is likely to cause adverse effects on the liver, immune system, development, and male and female reproductive systems in humans"
- Developmental toxicity: Decreased fetal body weight in mice with increasing dose (≥0.5 mg/kg-day); human epidemiological studies also showed decreased birth weight and length
- Male reproductive toxicity: Changes in sperm count, testosterone levels, and reproductive tissue pathology in rats following exposure (≥0.625 mg/kg-day)
- Female reproductive toxicity: Changes in uterine weight and estrous cycle in rats following exposure (≥1.25 mg/kg-day)
- Based on this, EPA developed lifetime and subchronic oral reference doses (RfD = 2×10⁻⁹ mg/kg-day)
3. Perfluorobutanoic Acid (PFBA, CASRN 375-22-4) and Related Salts
Basis: U.S. EPA IRIS Toxicological Review published in 2022
Listing Rationale: OEHHA determined that it meets listing criteria, based on three endpoints: developmental toxicity, male reproductive toxicity, and female reproductive toxicity
Key Findings:
- EPA Conclusion: "PFBA exposure is likely to cause developmental effects in humans," including increased prenatal effects and delayed developmental milestones (delayed eyelid opening, vaginal opening, and preputial separation)
- Reproductive developmental delay: Delayed vaginal opening and preputial separation following embryonic exposure in mice
- EPA developed a subchronic oral reference dose (RfD = 6×10⁻³ mg/kg-day), with developmental delay as the point of departure
- Note: EPA considers the evidence regarding PFBA's reproductive toxicity in adults as "inadequate," but the evidence for developmental effects as "moderate"
Potential Impact
Under the provisions of California Proposition 65, any business operating in California that sells products, operates facilities, or releases substances containing listed chemicals, and where exposure exceeds the safe harbor level, must provide clear and reasonable warnings to inform consumers or workers that the substance may cause cancer or reproductive toxicity. Warnings may be provided through various means, such as: labeling consumer products, posting notices in the workplace, distributing notifications at rental housing complexes, or publishing announcements in newspapers. The requirement to provide warnings becomes effective one year after the chemical is listed.
Furthermore, the proposition explicitly prohibits businesses from knowingly and intentionally discharging listed chemicals into any waters that may become a source of drinking water while conducting operations in California. Within twenty months from the date of listing, businesses must implement discharge control measures to ensure full compliance with this prohibition.
If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.

